NASDAQ:ALNA Allena Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allena Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.32 -0.02 (-1.49 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$1.28Now: $1.32▼$1.3650-Day Range$1.10MA: $1.34▼$1.5452-Week Range$0.53Now: $1.32▼$6.30Volume384,604 shsAverage Volume781,932 shsMarket Capitalization$50.32 millionP/E RatioN/ADividend YieldN/ABeta2.68 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAllena Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.67, Allena Pharmaceuticals has a forecasted upside of 632.3% from its current price of $1.32.Amount of Analyst CoverageAllena Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesAllena Pharmaceuticals has received 224 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllena Pharmaceuticals has received 210 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllena Pharmaceuticals has received 51.61% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllena Pharmaceuticals does not currently pay a dividend.Dividend GrowthAllena Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allena Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders38.60% of the stock of Allena Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.14% of the stock of Allena Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allena Pharmaceuticals are expected to grow in the coming year, from ($0.95) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allena Pharmaceuticals is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allena Pharmaceuticals is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllena Pharmaceuticals has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.72 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALNA Previous Symbol CUSIPN/A CIK1624658 Webwww.allenapharma.com Phone617-467-4577Debt Debt-to-Equity Ratio0.22 Current Ratio4.21 Quick Ratio4.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book1.81Profitability EPS (Most Recent Fiscal Year)($2.10) Net Income$-47,340,000.00 Net MarginsN/A Return on Equity-216.21% Return on Assets-119.10%Miscellaneous Employees34 Outstanding Shares38,119,000Market Cap$50.32 million Next Earnings Date11/11/2020 (Estimated) OptionableNot Optionable $1.32 -0.02 (-1.49 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ALNA News and Ratings via Email Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter. Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions How has Allena Pharmaceuticals' stock been impacted by Coronavirus? Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALNA stock has increased by 4.8% and is now trading at $1.32. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Allena Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allena Pharmaceuticals. When is Allena Pharmaceuticals' next earnings date? Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Allena Pharmaceuticals. How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals Inc (NASDAQ:ALNA) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.26) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.01. View Allena Pharmaceuticals' earnings history. What price target have analysts set for ALNA? 7 analysts have issued 12-month target prices for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $18.00. On average, they expect Allena Pharmaceuticals' stock price to reach $9.67 in the next year. This suggests a possible upside of 632.3% from the stock's current price. View analysts' price targets for Allena Pharmaceuticals. Are investors shorting Allena Pharmaceuticals? Allena Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,430,000 shares, an increase of 31.2% from the August 15th total of 1,090,000 shares. Based on an average trading volume of 1,320,000 shares, the days-to-cover ratio is currently 1.1 days. View Allena Pharmaceuticals' Short Interest. Who are some of Allena Pharmaceuticals' key competitors? Some companies that are related to Allena Pharmaceuticals include DBV TECHNOLOGIE/S (DBVT), ADMA Biologics (ADMA), CASI Pharmaceuticals (CASI), Axcella Health (AXLA), Fennec Pharmaceuticals (FENC), Ayala Pharmaceuticals (AYLA), GENFIT S A/ADR (GNFT), Lineage Cell Therapeutics (LCTX), INmune Bio (INMB), LogicBio Therapeutics (LOGC), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), TrovaGene (TROV), Erytech Pharma (ERYP) and Windtree Therapeutics (WINT). View all competitors. What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD), VBI Vaccines (vbiv) and Miragen Therapeutics (MGEN). Who are Allena Pharmaceuticals' key executives? Allena Pharmaceuticals' management team includes the following people: Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 67, Pay $427.95k)Dr. Louis Brenner, Pres, CEO & Director (Age 50, Pay $507.28k)Mr. Edward J. Wholihan, Chief Financial Officer (Age 60, Pay $387.03k)Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 55)Mr. Hugh Wight, Sr. VP of Technical Operations When did Allena Pharmaceuticals IPO? (ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Allena Pharmaceuticals' stock symbol? Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA." Who are Allena Pharmaceuticals' major shareholders? Allena Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Sabby Management LLC (6.19%), Worth Venture Partners LLC (1.03%), Jacobs Levy Equity Management Inc. (0.33%), Wedbush Securities Inc. (0.20%), Goldman Sachs Group Inc. (0.11%) and Advisor Group Holdings Inc. (0.08%). View institutional ownership trends for Allena Pharmaceuticals. Which major investors are selling Allena Pharmaceuticals stock? ALNA stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., and Algert Global LLC. View insider buying and selling activity for Allena Pharmaceuticals. Which major investors are buying Allena Pharmaceuticals stock? ALNA stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, Worth Venture Partners LLC, Goldman Sachs Group Inc., Wedbush Securities Inc., and Advisor Group Holdings Inc.. View insider buying and selling activity for Allena Pharmaceuticals. How do I buy shares of Allena Pharmaceuticals? Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Allena Pharmaceuticals' stock price today? One share of ALNA stock can currently be purchased for approximately $1.32. How big of a company is Allena Pharmaceuticals? Allena Pharmaceuticals has a market capitalization of $50.32 million. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe. What is Allena Pharmaceuticals' official website? The official website for Allena Pharmaceuticals is www.allenapharma.com. How can I contact Allena Pharmaceuticals? Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577. This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
